Strengthening Transplantation Effects of Bone Marrow Mononuclear Cells With Atorvastatin in Myocardial Infarction

NCT ID: NCT00979758

Last Updated: 2018-01-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-01-31

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The benefit of current stem cell transplantation therapy for myocardial infarction is limited by low survival rate for stem cell. The purpose of this study is to test whether intensive Atorvastatin therapy can improve the outcome of patients with impaired left ventricle function after myocardial infarction who underwent intracoronary transfer of autologous bone marrow cells.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The major challenge to a successful stem cell therapy for myocardial infarction is the low survival rate of implanted cells in the damaged tissue. Atorvastatin, an HMG-CoA reductase inhibitor, has multiple biological activities independent of cholesterol-lowering action.This study is performed to find out more information about the strategy with Atorvastatin therapy to improve the survival of implanted cells. autologous bone marrow stem cells transplantation. Patients between 30 and 80 years of age who receive autologous bone marrow stem cell transplant at the Fuwai cardiovascular hospital may be eligible for this study. These patients receive autologous bone marrow cells transplantation intracoronary undergoing Percutaneous Coronary Intervention with regular or high dose of Atorvastatin treatment. The objective evaluations will be performed at baseline and during 12 months follow-up.

Heart function tests may include the following:

1. Electrocardiogram (EKG) evaluates the electrical activity of the heart. Electrodes placed on the chest transmit information from the heart to a machine.
2. Echocardiogram (Echo) is an ultrasound test that uses sound waves to create an image of the heart and examine the function of the heart chambers and valves.
3. Gated acquisition scan is a nuclear medicine test that uses a small amount of radioactive chemical injected into a vein. A special scanner creates an image of the heart for examining the beating motion of the muscle.
4. MRI evaluates function of the heart chambers the beating motion of the muscle.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Infarction Stem Cell Transplantation Angioplasty, Transluminal, Percutaneous Coronary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Atorvastatin

Atorvastatin routine dose

Group Type SHAM_COMPARATOR

Atorvastatin and mononuclear cells transplantation

Intervention Type DRUG

Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation

Intensive Atorvastatin

Atorvastatin Intensive dose

Group Type PLACEBO_COMPARATOR

Atorvastatin and mononuclear cells transplantation

Intervention Type DRUG

Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation

Atorvastatin+Transplantation

Atorvastatin routine dose+ Mononuclear cells Transplantation

Group Type ACTIVE_COMPARATOR

Atorvastatin and mononuclear cells transplantation

Intervention Type DRUG

Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation

Intensive Atorvastatin+Transplantation

Atorvastatin intensive dose+ Mononuclear cells Transplantation

Group Type EXPERIMENTAL

Atorvastatin and mononuclear cells transplantation

Intervention Type DRUG

Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Atorvastatin and mononuclear cells transplantation

Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Statin Bone marrow stem cells transplantation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with coronary disease undergoing PCI.
2. At most 2 months since last episode of ST-elevation myocardial infarction.
3. Left ventricular ejection fraction \>=20% \<=45% based on coronary angiography or echocardiography.

Exclusion Criteria

1. Patients with non-ST-elevation myocardial infarction.
2. Patients with normal left ventricular function.
3. Patients with mechanical complications of myocardial infarction.
4. Patients with a malignant tumor.
5. Patients with infection disease.
6. Less than 6 months since last episode of stroke.
7. Patients with hematological disease (leukemia, myeloproliferative disease, or myelodysplastic syndromes).
8. AST (GOT) exceeding 100 IU/L or ALT (GPT) exceeding 100 IU/L.
9. Leukocytes less than 4,000/µL or exceeding 10,000/µL.
10. Platelets less than 100,000/µL.
11. Hemoglobin less than 10 g/dL.
12. Pregnant or nursing patients, those who may be pregnant, or those who plan on becoming pregnant before the end of the study period.
13. Any other reason that the Clinical Supervisors or Clinical Researchers may have for considering a case unsuitable for the study.
Minimum Eligible Age

30 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chinese Academy of Medical Sciences, Fuwai Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yuejin Yang

Vice president of Fuwai hospital

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yang yuejin, Doctor

Role: STUDY_DIRECTOR

Chinese Academy of Medical Sciences, Fuwai Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fuwai Hospital

Beijing, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

References

Explore related publications, articles, or registry entries linked to this study.

Yang YJ, Qian HY, Song L, Geng YJ, Gao RL, Li N, Wang H, Tian XQ, Huang J, Huang PS, Xu J, Shen R, Lu MJ, Zhao SH, Wu WC, Wu Y, Zhang J, Qian J, Xu JY, Xiong YY. Strengthening effects of bone marrow mononuclear cells with intensive atorvastatin in acute myocardial infarction. Open Heart. 2020 May;7(1):e001139. doi: 10.1136/openhrt-2019-001139.

Reference Type DERIVED
PMID: 32393654 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Fuwai Hospital 2009

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Stem Cell Injection in Cancer Survivors
NCT02509156 COMPLETED PHASE1
Endocardial Stem Cells Approach Efficacy
NCT00841958 COMPLETED PHASE3
Stem Cells in Myocardial Infarction
NCT00135928 COMPLETED PHASE2
Cell Therapy in Myocardial Infarction
NCT00350766 TERMINATED PHASE2/PHASE3